Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Adherence news

Show

From To
Linking HIV stigma, denial and poor health 

People living with HIV who stigmatise and think negatively about themselves because of their HIV status are less likely to start treatment and reach viral load suppression.

Published
08 November 2018
From
AVERT
Reaching the men: who are the partners of the young women with HIV in South Africa?

In the high-prevalence countries of southern Africa, young women under 25 bear the brunt of the epidemic, with continued high rates of HIV infection. So

Published
05 November 2018
By
Gus Cairns
How substance use affects adherence to PrEP among gay and bisexual men

On average, club drug users were no more likely to miss a dose of PrEP than non-club drug users. However, club drug use (at the event level) increased the odds of missing a dose on the same day by 55 percent and the next day (e.g., a "carryover effect") by 60 percent. "This suggests that although club drug users appeared to have similar aggregate levels of adherence, their missed doses were specifically timed around instances of club drug use.

Published
24 October 2018
From
Medical Xpress
Wide range of views about switching to weekly, monthly or biannual ART

Two-thirds of people taking combination antiretroviral therapy (cART) would be interested in switching to a once-weekly oral regimen should it become available, according to American research published in

Published
15 October 2018
By
Michael Carter
Stigma remains a substantial barrier in accessing HIV care in rural East Africa

A set of varied barriers adversely impact positive outcomes at different stages in the HIV care cascade in the rural East African context, according to a qualitative

Published
14 September 2018
By
Krishen Samuel
How smartphones are becoming a weapon in the global fight against tuberculosis

Mobile technologies devised by researchers at the University of California, San Diego, and Johns Hopkins are allowing patients to use their phones to record daily medication intake. The encrypted videos are sent to public health workers who can watch them from their cubicles, instead of traveling long distances every day to visit patients at their homes or workplaces.

Published
21 August 2018
From
STAT
Should Gilead Be Worried About This New Monthly HIV Medication?

Yesterday, Johnson & Johnson and ViiV Healthcare announced positive results from the Atlas phase 3 study testing their two-drug HIV treatment containing an investigational drug cabotegravir and rilpivirine, a nucleoside reverse transcriptase inhibitor (NRTI) sold by Johnson & Johnson as Edurant. The important thing here isn't going from three medications to two, but that ViiV and Johnson & Johnson's cabotegravir and rilpivirine combination is injected once a month compared to a daily therapy for the three-drug combination.

Published
16 August 2018
From
Motley Fool
HIV drug research in Wales to cut infection risk

Nearly 400 people have been taking part in a three-year trial of the drugs in Wales since last summer. Cardiff University will now examine how people have been taking the medicine - and if that affects the protection.

Published
16 August 2018
From
BBC
TAC: ARV treatment education best way to bring down HIV infection rates

An activist organisation, the Treatment Action Campaign (TAC), says that for South Africa to further decrease the rate of new HIV infections more needs to be done to curb treatment defaulting for persons on the ARV treatment programme.

Published
18 July 2018
From
Eyewitness News
Blood, Hair, or Urine? Weighing PrEP Adherence Options Beyond Self-Report

Understanding whether a person with a PrEP prescription is actually using the medication is something a provider may want to know. Currently, a few measures determine adherence to PrEP: self-report, hair, dried blood spot, and urine analysis. As of now, no one guideline or definitive standard is being used. Clinicians and researchers presented their recent findings at the 13th Annual Adherence Conference last month in Miami.

Published
16 July 2018
From
The Body Pro
← First12345...42Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.